Atlas Venture Fund XI, L.P.

Atlas Venture Fund XI, L.P. has filed trades across 7 companies (mainly through SEC (Form 4)), most often in Dyne Therapeutics, Inc., Xilio Therapeutics, Inc. and Day One Biopharmaceuticals, Inc. The record holds 66 filings, for trades running from 24 June 2019 to 10 February 2025.

Both buying and selling appear: 7 purchases worth €20.8M, against 38 sales worth €40.0M. On balance, insiders were net sellers of €19.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2025: 1 purchase and no sales on the market.

A typical purchase (the median) is worth €3.3M. Clusters matter here: 5 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 10 February 2025, the filings show a transaction in Sionna Therapeutics, Inc. The last purchase on record was published on 10 February 2025, which is 620 days ago. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.